Sub-Lingual Immunotherapy

Canonica, Giorgio Walter; Bousquet, Jean; Casale, Thomas B.; Lockey, Richard F.; Baena-Cagnani, Carlos E.; Pawankar, Ruby; Potter, Paul; Bousquet, Philippe; Cox, Linda; Durham, Stephen R.; Nelson, Harold S.; Passalacqua, Giovanni; Ryan, Dermot; Brožek, Jan; Compalati, Enrico; Dahl, Ronald; Delgado, Luis Mariano Mateos; Wijk, Roy Gerth van; Gower, Richard; Ledford, Dennis K.; Filho, Nelson Rosário; Valovirta, Erkka; Yusuf, Osman; Zuberbier, Torsten; Akhanda, Wahiduzzaman; Almarales, Raúl Castro; Ansotegui, Ignacio J.; Bonifazi, F.; Ceuppens, Jan; Chivato, Tomás; Dimova, D.; Dumitraşcu, Dinu Iuliu; Fontana, Luigi; Katelaris, Constance H.; Kaulsay, Ranbir; Kuna, Piotr; Larenas-Linnemann, Désirée; Manoussakis, Manolis; Nékám, K; Nunes, Carlos Pereira; O’Hehir, Robyn E; Olaguibel, José María; Onder, Nerin Bahceciler; Park, Jung Won; Priftanji, Alfred; Puy, Robert; Sarmiento, L. F.; Scadding, Glenis K.; Schmid‐Grendelmeier, Peter; Seberová, Ester; Sepiashvili, Revaz; Solé, Dírceu; Togias, Alkis; Tomino, Carlo; Toskala, Elina; Beever, Hugo Van; Vieths, Stefan

doi:10.1097/wox.0b013e3181c6c379

Cited by 98 publications

(24 citation statements)

References 341 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The World Health Organization [24,25] recommends a treatment period of 3-5 years for allergen-specific immunotherapy. SLIT using grass pollen tablets has been found to have a disease-modifying effect at the 2-year follow-up after 3 years of treatment [26].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis

Okamoto

Okubo

Yonekura

et al. 2015

Int Arch Allergy Immunol

109

View full text Add to dashboard Cite

Background: Japanese cedar (JC) pollinosis is the most common seasonal allergic rhinitis in Japan. Standardized JC pollen extract is available for subcutaneous immunotherapy, but this treatment is limited by potentially serious side effects. The aim of this double-blind, randomized comparative study was to evaluate the efficacy and safety of standardized JC pollen extract in a new oral formulation (CEDARTOLEN®, Torii Pharmaceutical Co., Ltd., Tokyo, Japan) for sublingual immunotherapy (SLIT) for JC pollinosis. Methods: A total of 531 subjects with JC pollinosis were randomized into 2 groups at a ratio of 1:1 to receive daily sublingual administration of standardized JC pollen extract with a maintenance dose of 2,000 Japanese allergy units (JAU) or placebo for 2 consecutive pollen seasons. The efficacy was evaluated using the total nasal symptom and medication score (TNSMS) as the primary end point. Secondary end points included the total ocular symptom and medication score (TOSMS) and scores for individual symptoms and medication. Results: The TNSMS was significantly lower (p < 0.0001) in the SLIT group than in the placebo group in the peak symptom period by 18 and 30% in the first and second seasons, respectively. All secondary end points were also significantly lower in the SLIT group in both seasons. No systemic anaphylaxis occurred. Conclusions: SLIT with daily administration of standardized JC pollen extract was effective for improving nasal and ocular symptoms of JC pollinosis and reducing the use of relief medication. The JC pollen extract was well tolerated with only local adverse events.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis

Okamoto

Okubo

Yonekura

et al. 2015

Int Arch Allergy Immunol

109

View full text Add to dashboard Cite

show abstract

“…SLIT involves placing drops of allergen extract under the tongue, then swallowing the liquid. SLIT has some convincing evidence for efficacy in allergies to pollens (i.e., allergic rhinitis) and is extensively used in Europe [39,40]. This type of therapy is thought to work by interacting with tolerogenic Langerhan's cells in the oral mucosa, which lead to down-regulation of the allergic response.…”

Section: Sublingual Immunotherapymentioning

confidence: 99%

Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response

2010

View full text Add to dashboard Cite

There is no approved therapy for food allergies, which affect 12 million people in the United States and millions more worldwide. In the last few years, our research team at Duke has begun to develop protocols to treat peanut and other food allergies. Two distinct therapies are being developed. Oral immunotherapy (OIT), which relies on ingestion of increasing amounts of the allergenic food, has been used to successfully desensitize more than 50 peanut allergic subjects. Sublingual immunotherapy (SLIT) involves placing small quantities of peanut allergens under the tongue and has shown promise in our initial placebo-controlled clinical trial. Immunologic changes associated with OIT and SLIT include reduction in mast cell reactivity as determined by skin prick test size, decreased basophil responses, decreased specific-IgE, increased IgG4, and induction of regulatory T cells. Development of these immunotherapy strategies has generated much excitement in the food allergy community; however, further studies are needed before these approaches are ready for clinical use.

show abstract

“…In sublingual immunotherapy (SLIT), specific allergen extracts are delivered into the oral cavity, as opposed to subcutaneous immunotherapy (SCIT) (Bousquet PJ et al 2009, Radulovic S et al 2011). This treatment is widely used in Europe to treat allergic respiratory disease and atopic dermatitis in humans (Cadario G et al 2007, Bousquet PJ et al 2009).…”

Section: Introductionmentioning

confidence: 99%

“…This treatment is widely used in Europe to treat allergic respiratory disease and atopic dermatitis in humans (Cadario G et al 2007, Bousquet PJ et al 2009). Furthermore, this treatment is being used to treat CAD in the United States (Olivry T et al 2015, DeBoer DJ et al 2016).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study

Fujimura¹,

Ishimaru²

2016

Polish Journal of Veterinary Sciences

View full text Add to dashboard Cite

Twenty dogs with canine atopic dermatitis (CAD) were treated with rush sublingual immunotherapy (SLIT), with a 48 hour build-up phase and 6 months maintenance phase (treated by antigen once every 3-4 weeks). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (baseline) and after 6 months. An open, non-controlled, non-randomized pilot trial was conducted to assess the effectiveness and safety of rush SLIT for environmental allergen extracts (Dematophagoides pteronyssinus and D.farinae mix and other). Three dogs dropped out and 17 dogs finished the trial. CADESI-4 at baseline was 60.6±27.1 (range 17-107, n=17). After 6 months of SLIT treatment, CADESI-4 was 37.4±36.0 (range 5-152, n=17) (p <0.01), which was a 38.3% reduction. A significant improvement, defined as a CADESI-4 reduction of > 30%, was observed in 13 out of 17 dogs (76%). A moderate improvement, defined as a CADESI-4 reduction of < = 30%, was observed in 2 dogs (12%). In the other 2 dogs (12%), CADESI-4 worsened or showed no change. However, no severe adverse effects were observed during the trial.Therefore, rush SLIT against environmental allergen extract for CAD showed effectiveness and safety as evidenced by the reduction of CADESI-4 after 6 months SLIT without severe adverse effects.

show abstract

Sub-Lingual Immunotherapy

Cited by 98 publications

References 341 publications

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis

Efficacy and Safety of Sublingual Immunotherapy for Two Seasons in Patients with Japanese Cedar Pollinosis

Pioneering immunotherapy for food allergy: clinical outcomes and modulation of the immune response

Rush sublingual immunotherapy in canine atopic dermatitis: a prospective pilot study

Contact Info

Product

Resources

About